4547 — Kissei Pharmaceutical Co Balance Sheet
0.000.00%
- ¥172bn
 - ¥125bn
 - ¥88bn
 
- 58
 - 45
 - 88
 - 74
 
Annual balance sheet for Kissei Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st  | 2022 March 31st  | 2023 March 31st  | 2024 March 31st  | 2025 March 31st  | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho | 
| Standards: | JAS | JAS | JAS | JAS | JAS | 
| Status: | Final | Final | Final | Final | Final | 
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 44,454 | 53,152 | 49,599 | 45,933 | 48,654 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 23,058 | 22,806 | 22,779 | 28,679 | 29,653 | 
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 92,965 | 99,342 | 100,641 | 104,551 | 106,980 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 24,290 | 24,074 | 24,579 | 24,861 | 27,069 | 
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 268,861 | 238,087 | 221,200 | 260,929 | 244,059 | 
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 18,245 | 18,744 | 14,957 | 17,663 | 16,578 | 
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 49,546 | 36,701 | 27,300 | 40,900 | 35,055 | 
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 219,315 | 201,386 | 193,900 | 220,029 | 209,004 | 
| Total Liabilities & Shareholders' Equity | 268,861 | 238,087 | 221,200 | 260,929 | 244,059 | 
| Total Common Shares Outstanding |